Pregabalin Capsule
Product Images NDC 50090-7983

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50090-7983). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907983)

Label for Pregabalin 200 mg capsules by A-S Medication Solutions. The label indicates a 60-capsule package for oral use. It includes dosage strength, storage instructions (store at 68 to 77 degrees Fahrenheit), and a barcode. The label also shows the product NDC 50090-7983-0 and the packaging site location in Libertyville, Illinois.*

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

This line graph shows the percent of patients improved versus percent improvement in pain from baseline for pregabalin at various dosages (200 mg, 100 mg, 25 mg three times a day) and placebo. The graph compares patient improvement over a range of pain reduction percentages.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A Kaplan-Meier survival curve comparing the estimated percentage of subjects without loss of therapeutic response (LTR) over 180 days between Pregabalin and placebo groups. The y-axis shows the estimated percentage without LTR, and the x-axis shows the study duration in days. Two lines represent Pregabalin (solid) and placebo (dashed).*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line graph comparing the percent of subjects improved over time from baseline to Week 12 using the RCOF measure. The x-axis represents percent improvement from baseline to Week 12, and the y-axis shows the percent of subjects improved. Two lines are shown: a solid line for Pregabalin and a dashed line for Placebo, with Pregabalin showing a higher percentage of subjects improved across the range.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph depicting the percent of subjects improved over time from baseline to week 16 BOCF for Pregabalin versus placebo. The x-axis shows percent improved from baseline to week 16, while the y-axis indicates the percent of subjects improved. The graph includes two lines: a solid line for Pregabalin and a dashed line for placebo, demonstrating comparative improvement trends.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day and placebo. It shows two curves plotting patient improvement over a range of percent pain improvement values.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin doses of 300 mg, 150 mg, 75 mg taken two times a day and placebo. The graph compares efficacy of the different doses in improving patient pain levels over a range of improvement percentages.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing trends of patient improvement over different levels of pain improvement.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. Two vertical lines mark specific improvement thresholds on the x-axis.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

Bar chart comparing responder rates (%) across different dosages of Pregabalin and placebo in two studies labeled E1 and E3. The x-axis shows treatment groups with varying doses including placebo, and the y-axis shows responder rates ranging from 0% to 60%. Doses range from 50 mg/day to 600 mg/day, with BID and TID administration noted. Statistically significant results versus placebo are marked with an asterisk.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A dose-response line graph showing seizure reduction as median percentage change from baseline versus dose in mg/day for pregabalin. The graph includes data points from four studies labeled E1 BID, E2 TID, E3 BID, and E3 TID with corresponding markers. Significant p-values are indicated at several dose points, showing increased seizure reduction with higher doses.*

FDA Label Image

Pregabalinfigure8 (Pregabalinfigure8)

A bar chart displaying responder rates (%) for three groups: Placebo (22.6%), 2.5 mg/kg/day Pregabalin (29.1%), and 10 mg/kg/day Pregabalin (40.6%). Below the bars, sample sizes are 93, 103, and 96 respectively.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph showing percent of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. It compares the effects of Pregabalin at 600 mg, 450 mg, 300 mg daily doses, and placebo. The graph illustrates trends of patient response across these different dose levels.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure of pregabalin displaying its molecular formula with amino, methyl, and carboxyl functional groups clearly depicted in a line-bond diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.